Skip to main content
. 2016 Dec 9;8(3):4277–4288. doi: 10.18632/oncotarget.13834

Figure 4. Time-dependent increase in HER3 phosphorylation does not occur upon lapatinib treatment.

Figure 4

LIM1215 cells were treated with (A) lapatinib (1 μM), (C) cetuximab (50 μg/mL) and trastuzumab (20 μg/mL) or (D) cetuximab (50 μg/mL) and pertuzumab (10 μg/mL) for 24h and heterodimer formation between EGFR family members as well as both total and phosphorylated levels of EGFR were assessed by CEER by Prometheus Laboratories Inc. San Diego, CA (USA). The results are expressed as mean ± SEM. A total of 6 microarray spots were analyzed for each sample. CU: computed unit. (B) LIM1215 and HCA7 cells were treated with lapatinib (1 μM) for different time points. Protein levels were detected by western blotting as described in the Materials and Methods section.